Facial Palsy As a Side Effect of Vemurafenib Treatment in Patients With Metastatic Melanoma

2013 ◽  
Vol 31 (12) ◽  
pp. e215-e217 ◽  
Author(s):  
Oliver Klein ◽  
Antoni Ribas ◽  
Bartosz Chmielowski ◽  
Grant Walker ◽  
Arthur Clements ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Facial Palsy ◽  
Side Effect

scholarly journals A Case of Immune Thrombocytopenia as a Rare Side Effect of an Immunotherapy with PD1-Blocking Agents for Metastatic Melanoma

2017 ◽  
Vol 44 (6) ◽  
pp. 426-428 ◽  
Author(s):  
Claudia Pföhler ◽  
Hermann Eichler ◽  
Barbara Burgard ◽  
Nathalie Krecké ◽  
Cornelia S.L. Müller ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Side Effect ◽  
Immune Thrombocytopenia ◽  
Blocking Agents ◽  
Rare Side Effect

scholarly journals A bilateral optic neuritis side effect of biological treatment with pembrolizumab in a patient with metastatic melanoma

2020 ◽  
Vol 10 (5) ◽  
pp. 171-178
Author(s):  
Andrea Nassar ◽  
Neiby Rivera ◽  
Javier Mora ◽  
Ayleen Martinez
Keyword(s):  
Optic Neuritis ◽  
Metastatic Melanoma ◽  
Immune Checkpoint ◽  
Side Effect ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Humanized Monoclonal Antibody ◽  
History Of ◽  
High Doses ◽  
Overall Survival Benefit

Pembrolizumab is an anti-PD-1 humanized monoclonal antibody, standardized therapy for the treatment of metastatic melanoma, providing an overall survival benefit to patients; however, it may be associated with immune-related adverse effects (irAE). We describe the case of a patient with a history of metastatic melanoma undergoing treatment with pembrolizumab, who presented visual acuity deterioration due to inflammatory involvement of the optic nerves. There are few reported cases of an optic neuritis side effect of treatment with immune checkpoint inhibitors. The patient received high doses of steroids and plasmapheresis with improved light perception. This case highlights the need to recognize atypical processes, mediated by the immune system, associated with treatment with immune checkpoint inhibitors (ICI), including pembrolizumab.

scholarly journals A neurologist’s rhombencephalitis after comirnaty vaccination. A change of perspective

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Alexander Walter ◽  
Markus Kraemer
Keyword(s):  
Facial Palsy ◽  
Side Effect ◽  
Orphan Disease ◽  
Immunological Reaction ◽  
Limb Ataxia ◽  
Change Of Perspective ◽  
Personal Case ◽  
Multiple Causes

AbstractRhombencephalitis is an orphan disease of multiple causes that may manifest with facial palsy, limb ataxia and reduced consciousness. Up to now it is described after COVID-19 infection and in this (personal) case was found up to 8 weeks after Comirnaty vaccination. So far, we do not fully understand the pathophysiological characteristics of encephalitis associated with SARS-CoV-2. In rare cases, vaccination may cause an immunological reaction and delayed inflammation, the consequences of which we have not yet deciphered. Rhombencephalitis should be considered as a rare potential mRNA-associated vaccination side effect.

scholarly journals Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update

2020 ◽  
Vol 18 (6) ◽  
pp. 582-609
Author(s):  
Katharina C. Kähler ◽  
Jessica C. Hassel ◽  
Lucie Heinzerling ◽  
Carmen Loquai ◽  
Kai‐Martin Thoms ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Immune Checkpoint ◽  
Side Effect ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade

Conjunctival oedema: a side-effect of cyclosporin toxicity and a consequence of obesity

1996 ◽  
Vol 135 (1) ◽  
pp. 146-147 ◽  
Author(s):  
E. Papadavid ◽  
J. Yell ◽  
T.J. Ryan
Keyword(s):  
Side Effect

Abstract #917: Ipilimumab Induced Hypophysitis in a Patient with Metastatic Melanoma

2016 ◽  
Vol 22 ◽  
pp. 202
Author(s):  
Samaneh Dowlatshahi ◽  
Ronald A. Codario
Keyword(s):  
Metastatic Melanoma
Sign in / Sign up

Export Citation Format

Share Document